{
  "abstract": "CD19CAR T cells demonstrate remarkable therapeutic efficacy in the treatment of B cell malignancies. A global limitation of conventional CD19CAR therapy is its mono-specificity. Thus, defining complementary targets to CD19 is critical to avoid target-dependent limitations. Alternatives to protein antigens include secondary modifications, such as glycosylation. One example of aberrant glycosylation in lymphoma is the increase in N-glycans capped with α2,6-linked sialic acid, named CD75s. Here, we generate a CAR that recognizes CD75s based on an IgM monoclonal antibody called HH2. HH2CAR shows cytotoxic activity against B cell lymphoma cell lines, although it induces little to no cytokine release. However, while HH2CAR alone cannot control tumor progression in vivo, its combination with CD19CAR results in a functional molecule. Beyond overcoming the limited efficiency of HH2CAR T cells, this combination also prevents potential off-tumor/on-target toxicity associated with CD19 single targeting. Thus, inefficient mono-specific CAR molecules can be effectively leveraged in combinatorial formats.",
  "abstract_shown": true,
  "affiliations": [
    "Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, 0379 Oslo, Norway",
    "Faculty of Medicine, University of Oslo, 0316 Oslo, Norway",
    "Faculty of Mathematics and Natural Sciences, University of Oslo, 0315 Oslo, Norway",
    "i3S, Institute for Investigation and Innovation in Health, University of Porto, 4200-135 Porto, Portugal",
    "IPATIMUP – Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal",
    "Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0310 Oslo, Norway",
    "Department of Clinical Science, Precision Oncology Research Group, University of Bergen, 5020 Bergen, Vestland, Norway",
    "Centre for Cancer Biomarkers (CCBIO), University of Bergen, 5020 Bergen, Vestland, Norway",
    "Centre for Pharmacy, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway",
    "Department of Haematology, Haukeland University Hospital, 5020 Bergen, Vestland, Norway"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 18,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Christopher Forcados"
    },
    {
      "affs": [
        0
      ],
      "name": "Hakan Köksal"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Eveline Scherer"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Rafaela Abrantes"
    },
    {
      "affs": [
        0
      ],
      "name": "Pierre Dillard"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Henrique O. Duarte"
    },
    {
      "affs": [
        5
      ],
      "name": "Sarah Josefsson"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Catarina Gomes"
    },
    {
      "affs": [
        6,
        7
      ],
      "name": "Constance de Montlaur"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Henrik T.Z. Hellesøy"
    },
    {
      "affs": [
        6,
        7,
        8
      ],
      "name": "Ryan Dunkel"
    },
    {
      "affs": [
        5
      ],
      "name": "Erlend.B. Smeland"
    },
    {
      "affs": [
        5
      ],
      "name": "June H. Myklebust"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Celso A. Reis"
    },
    {
      "affs": [
        6,
        7,
        8,
        9
      ],
      "name": "Emmet McCormack"
    },
    {
      "affs": [
        6,
        7,
        9
      ],
      "name": "Pascal Gelebart"
    },
    {
      "affs": [
        0
      ],
      "name": "Else Marit Inderberg"
    },
    {
      "affs": [
        0
      ],
      "name": "Sébastien Wälchli"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/9fbbenxrb2bb7.bib",
  "cited_by": 0,
  "doi": "10.1016/j.xcrm.2026.103108",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13710698/",
  "id": "9fbbenxrb2bb7",
  "issns": [
    "2666-3791"
  ],
  "landing_url": "https://doi.org/10.1016/j.xcrm.2026.103108",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Article"
    ],
    [
      "openalex",
      "2730|CAR-T cell therapy research"
    ]
  ],
  "openalex": "W7221014321",
  "pdf_url": null,
  "pmcid": "PMC13710698",
  "pmid": "42849448",
  "published": "2026-10-08",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/9fbbenxrb2bb7.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T12:21:37Z",
      "native_id": "PMC13710698",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.xcrm.2026.103108"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|CAR-T cell therapy research",
      "subfield": "oncology"
    }
  ],
  "title": "Reviving low-affinity glycan-targeting CAR with combinatorial design",
  "title_text": "Reviving low-affinity glycan-targeting CAR with combinatorial design",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T12:21:37Z",
  "url": "https://research.draconitic.com/paper/9fbbenxrb2bb7",
  "venue": "Cell Reports Medicine",
  "versions": []
}